Effects of PPAR agonists on proliferation and differentiation in human urothelium.

[1]  J. Southgate,et al.  Structurally diverse peroxisome proliferator‐activated receptor agonists induce apoptosis in human uro‐epithelial cells by a receptor‐independent mechanism involving store‐operated calcium channels , 2009, Cell proliferation.

[2]  Jennifer Southgate,et al.  Sensitivity of Normal, Paramalignant, and Malignant Human Urothelial Cells to Inhibitors of the Epidermal Growth Factor Receptor Signaling Pathway , 2008, Molecular Cancer Research.

[3]  J. Southgate,et al.  Differentiation potential of urothelium from patients with benign bladder dysfunction , 2007, BJU international.

[4]  M. Cano,et al.  Subchronic urinary bladder effects of muraglitazar in male rats. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  Samuel M. Cohen,et al.  Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARα/γ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action , 2006, Toxicologic pathology.

[6]  J. Southgate,et al.  PPARγ‐regulated tight junction development during human urothelial cytodifferentiation , 2006, Journal of cellular physiology.

[7]  Béatrice Desvergne,et al.  From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.

[8]  S. Cohen.  Effects of PPARγ and Combined Agonists on the Urinary Tract of Rats and Other Species , 2005 .

[9]  J. Southgate,et al.  Urothelial differentiation in chronically urine-deprived bladders of patients with end-stage renal disease. , 2005, Kidney international.

[10]  L. Iversen,et al.  Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo , 2005, Toxicologic pathology.

[11]  Jennifer Southgate,et al.  Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. , 2005, Experimental cell research.

[12]  J. Berger,et al.  PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.

[13]  L. Iversen,et al.  Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo , 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[14]  R. D. Lynch,et al.  The tight junction: a multifunctional complex. , 2004, American journal of physiology. Cell physiology.

[15]  J. Southgate,et al.  Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. , 2004, The American journal of pathology.

[16]  J. Southgate,et al.  Role of PPAR γ and EGFR signalling in the urothelial terminal differentiation programme , 2004, Journal of Cell Science.

[17]  G. Hall,et al.  Uroplakin gene expression in normal human tissues and locally advanced bladder cancer , 2003, The Journal of pathology.

[18]  Fang-Ming Deng,et al.  Role of membrane proteins in permeability barrier function: uroplakin ablation elevates urothelial permeability. , 2002, American journal of physiology. Renal physiology.

[19]  K. Kihara,et al.  PPARγ ligands suppress proliferation of human urothelial basal cells in vitro , 2002 .

[20]  J. Southgate,et al.  Culture of Human Urothelium , 2002 .

[21]  J. Southgate,et al.  Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. , 1999, Histology and histopathology.

[22]  G. Hall,et al.  Uroplakin gene expression by normal and neoplastic human urothelium. , 1998, The American journal of pathology.

[23]  J. Reddy,et al.  Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. , 1998, The American journal of pathology.

[24]  M. Breyer,et al.  Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. , 1997, American journal of physiology. Renal physiology.

[25]  J. Southgate,et al.  Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. , 1997, Journal of clinical pathology.

[26]  S. Hayward,et al.  Growth factors in bladder wound healing. , 1997, The Journal of urology.

[27]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[28]  S. Tafuri,et al.  Regulation of Peroxisome Proliferator-activated Receptor γ Activity by Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.

[29]  M. Lazar,et al.  Transcriptional Activation by Peroxisome Proliferator-activated Receptor γ Is Inhibited by Phosphorylation at a Consensus Mitogen-activated Protein Kinase Site* , 1997, The Journal of Biological Chemistry.

[30]  D. F. Thomas,et al.  Normal human urothelial cells in vitro: proliferation and induction of stratification. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[31]  T. Sun,et al.  Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. , 1994, The Journal of biological chemistry.

[32]  J. Gosling,et al.  The morphology of normal human bladder urothelium. , 1989, Journal of anatomy.

[33]  S. Cohen.  Toxic and nontoxic changes induced in the urothelium by xenobiotics. , 1989, Toxicology and applied pharmacology.

[34]  R. Hicks.  THE MAMMALIAN URINARY BLADDERAN ACCOMMODATING ORGAN , 1975 .

[35]  M. Cano,et al.  Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. , 2006, Toxicologic pathology.

[36]  S. Cohen.  Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[37]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[38]  K. Kihara,et al.  PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. , 2002, Journal of cellular physiology.

[39]  R. Hicks.  The mammalian urinary bladder: an accommodating organ. , 1975, Biological reviews of the Cambridge Philosophical Society.